The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Predicting clinical outcomes after immunotherapy
Marco Donia, MD, PhD, Copenhagen University Hospital, Herlev, Denmark, highlights the importance of predicting clinical outcomes after immunotherapy for two main reasons. Firstly, to administer the treatment only to patients who have a reasonable chance of responding positively. Secondly, to spare patients with a low or zero likelihood of responding from potential side effects. The goal is to identify patients who are likely to respond well with minimal side effects and, conversely, those who may not respond well and are at a higher risk of adverse effects. This personalized approach aims to optimize the efficacy of immunotherapy while minimizing the potential negative impact on patients. The interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
